Trial ID or NCT#

NCT02586415

Status

not recruiting iconNOT RECRUITING

Purpose

This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.

Official Title

Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3

Eligibility Criteria

Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Maarten Lansberg, MD, PhD
Maarten Lansberg, MD, PhD
Stroke and vascular neurologist, General neurologist
Professor of Neurology and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Gregory W. Albers, MD
Gregory W. Albers, MD
Stroke and vascular neurologist
The Coyote Foundation Professor and Professor, by courtesy, of Neurosurgery at the Stanford University Medical Center
Jeremy J. Heit, MD, PhD
Jeremy J. Heit, MD, PhD
Interventional neuroradiologist
Assistant Professor of Radiology (Neuroimaging and Neurointervention) and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Neil Schwartz, MD, PhD
Neil Schwartz, MD, PhD
Stroke and vascular neurologist, Neurohospitalist, General neurologist
Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery
Michael P. Marks, MD
Michael P. Marks, MD
Interventional neuroradiologist, Radiologist
Professor of Radiology (General Radiology), Emeritus

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM